BIOCYTOGEN-B(02315),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02315 BIOCYTOGEN-B

Not Yet Opened 07-15 16:08:35

58.850

+6.050

+11.46%

High60.350	Low52.150	Vol4.72M
Open54.000	D1 Closing52.800	Amplitude15.53%
Mkt Cap26.31B	Tradable Cap6.53B	Total Shares447.00M
T/O274.06M	T/O Rate4.26%	Tradable Shares111.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"BIOCYTOGEN-B","latestPrice":58.85,"timestamp":1784102915004,"preClose":52.8,"halted":0,"volume":4724194,"delay":0,"changeRate":0.11458333333333343,"floatShares":111000000,"shares":447000000,"eps":0.43,"marketStatus":"Not Yet Opened","change":6.05,"latestTime":"07-15 16:08:35","open":54,"high":60.35,"low":52.15,"amount":274059104,"amplitude":0.155303,"askPrice":59.2,"askSize":1000,"bidPrice":58.85,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.736,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1784165400000},"marketStatusCode":0,"adr":0,"listingDate":1661961600000,"exchange":"SEHK","adjPreClose":52.8,"openAndCloseTimeList":[[1784079000000,1784088000000],[1784091600000,1784102400000]],"volumeRatio":3.441495593633596,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688796","market":"SH","secType":"STK","nameCN":"Biocytogen Pharmaceuticals (Beijing) Co.,Ltd.","latestPrice":131.93,"timestamp":1784098800000,"preClose":117.4,"halted":0,"volume":4398500,"delay":0,"premium":"-61.48"}},"requestUrl":"/m/hq/s/02315","defaultTab":"news","newsList":[{"id":"1148673440","title":"BIOCYTOGEN-B Shares Surge Over 14% Following Strategic Global Partnership Announcement for BsADC Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1148673440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148673440?lang=en_us&edition=fundamental","pubTime":"2026-07-10 11:18","pubTimestamp":1783653507,"startTime":"0","endTime":"0","summary":"Shares of BIOCYTOGEN-B (02315) have surged more than 14% in today's trading session.At the time of writing, the stock is up 13.94% to HK$53.55, with a trading turnover of HK$51.74 million. Catalyst...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","KCAI","ADC","BK0216","BK4080","688796","BK4585","BK4588","02315","BK1161","NETL","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143270232","title":"E Fund Management Increases Stake in Biocytogen by 91,500 Shares at HK$46.90 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1143270232","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143270232?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:34","pubTimestamp":1783510464,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange reveals that on July 2nd, E Fund Management Co., Ltd. purchased an additional 91,500 shares of Biocytogen Pharmaceuticals (Beijing) Co.,Ltd. (HKEX:...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","EWH","688796","BK1161","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114021760","title":"Biocytogen reports stable 446.90 million authorised shares and confirms public-float compliance for June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1114021760","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114021760?lang=en_us&edition=fundamental","pubTime":"2026-07-03 15:06","pubTimestamp":1783062369,"startTime":"0","endTime":"0","summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. released its Monthly Return for Equity Issuer and Hong Kong Depositary Receipts for the period ended 30 June 2026, showing no changes in either...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647374356","title":"Shanghai Court Dismisses HBM Subsidiary's Patent Infringement Claim Against Biocytogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2647374356","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647374356?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:46","pubTimestamp":1782737188,"startTime":"0","endTime":"0","summary":"Biocytogen Pharmaceuticals (Beijing) (HKG:2315) scored a legal win in China after a court dismissed a claim made by HBM (HKG:2142) subsidiary Harbour Antibodies.Specifically, the Shanghai Intellectual","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DRAM","RAM","BK1574","BK4588","BK1161","02315","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647327725","title":"Chinese Biopharma Stocks Rally as Investors Favor Healthcare over AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2647327725","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647327725?lang=en_us&edition=fundamental","pubTime":"2026-06-29 17:33","pubTimestamp":1782725580,"startTime":"0","endTime":"0","summary":"Chinese biopharma stocks rallied on Monday, as investors moved away from artificial-intelligence stocks amid concerns over overstretched valuations.Shares of BeOne Medicines led gains among biopharma ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTY","LU1303224171.USD","BK1571","LU2328871848.SGD","86618","ISBC","XBI","IE00BPRC5H50.USD","LU2039709279.SGD","LU0405327494.USD","XLV","BK1502","LABU","06618","BK1189","BK0196","BK0216","BK1191","BK4585","LU1993786604.SGD","BK0239","BK1583","688180","AIPO","01877","09637","BK4137","LU1808992512.USD","01093","603259","ONC","00241","HCSG","BK0028","LU1807302812.USD","02315","LU1255011170.USD","LU1008478684.HKD","LU0315179316.USD","600276","BK0012","BK1161","IE00BZ08YS42.EUR","LU0140636845.USD","LU0456827905.SGD","LU1226287529.USD","01801","AGIX","LU1251922891.USD","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142692214","title":"BIOCYTOGEN-B Shares Surge Over 16% as Core Innovation Strength Gains Further Recognition, RenMice® Platform Undergoes Major Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1142692214","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142692214?lang=en_us&edition=fundamental","pubTime":"2026-06-29 11:20","pubTimestamp":1782703231,"startTime":"0","endTime":"0","summary":"Shares of BIOCYTOGEN-B (02315) surged more than 16%. At the time of writing, the stock was up 14.57% to HK$46.4, with a turnover of HK$94.806 million.The significant move follows the company's recent...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","02315","BK4588","688796","BK1161","BK0216","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129467486","title":"E Fund Management Increases Stake in Biocytogen by 207,000 Shares at HK$40.63 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1129467486","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129467486?lang=en_us&edition=fundamental","pubTime":"2026-06-10 19:30","pubTimestamp":1781091022,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on June 4, E Fund Management Co., Ltd. increased its holding in Biocytogen-B (02315) by 207,000 shares. The purchase price was...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","BK1161","688796","02315","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183105660","title":"Biocytogen-B Shares Surge Over 6% on New AI Platform Launch and Accelerating Antibody Business","url":"https://stock-news.laohu8.com/highlight/detail?id=1183105660","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183105660?lang=en_us&edition=fundamental","pubTime":"2026-06-09 14:34","pubTimestamp":1780986886,"startTime":"0","endTime":"0","summary":"Shares of Biocytogen-B (02315) have risen by more than 6%. At the time of writing, the stock is up 4.11% to HK$40.5, with a turnover of approximately HK$48.83 million. A recent research report...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","CHAT","BK1161","BK4588","02315","AGIX","BK0216","ARTY","VXUS","BK4585","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113285604","title":"Shenwan Hongyuan Initiates Coverage on Biocytogen-B with \"Buy\" Rating, Citing AI-Enhanced Global Drug Discovery","url":"https://stock-news.laohu8.com/highlight/detail?id=1113285604","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113285604?lang=en_us&edition=fundamental","pubTime":"2026-06-05 14:48","pubTimestamp":1780642133,"startTime":"0","endTime":"0","summary":"Shenwan Hongyuan has released a research report forecasting that BIOCYTOGEN-B (02315) will achieve net profits attributable to the parent company of 423 million, 661 million, and 956 million yuan for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","AIPO","BK0276","BK1161","688796","BK0012","BK0188","000166","02315","ARTY","CHAT","BK0183","AGIX","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176922248","title":"Biocytogen Pharmaceuticals Schedules 25 June 2026 EGM; Seeks 10% H-Share Buy-back and Issuance Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1176922248","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176922248?lang=en_us&edition=fundamental","pubTime":"2026-06-04 23:03","pubTimestamp":1780585387,"startTime":"0","endTime":"0","summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has convened its 2026 second extraordinary general meeting (EGM) for 2:00 p.m. on 25 June 2026. The hybrid session will be held physically at the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160887032","title":"Fuguo Fund Increases Stake in Biocytogen by 950,000 Shares at HK$45.11 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1160887032","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160887032?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:30","pubTimestamp":1780576240,"startTime":"0","endTime":"0","summary":"Recent data from the Hong Kong Stock Exchange reveals that on June 1st, Fuguo Fund purchased an additional 950,000 shares of Biocytogen Pharmaceuticals (Beijing) Co.,Ltd. (HKEX: 02315).The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","EWH","BK0216","688796","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146835875","title":"Biocytogen Updates Articles of Association: 446.90 Million Shares, 9-Member Board and Minimum 10% Cash Dividend Policy","url":"https://stock-news.laohu8.com/highlight/detail?id=1146835875","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146835875?lang=en_us&edition=fundamental","pubTime":"2026-05-21 22:22","pubTimestamp":1779373367,"startTime":"0","endTime":"0","summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. released its revised Articles of Association (effective May 2026), setting out comprehensive rules for capital structure, corporate governance, profit...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118832957","title":"BIOCYTOGEN-B Surges Over 6% in Early Trading as RenBiologics Unit Enters Commercialization Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1118832957","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118832957?lang=en_us&edition=fundamental","pubTime":"2026-05-20 11:14","pubTimestamp":1779246880,"startTime":"0","endTime":"0","summary":"BIOCYTOGEN-B (02315) rose more than 6% in early trading. As of press time, the stock was up 6.03% to HK$50.85, with a turnover of HK$42.8952 million. The company recently participated in the AACR...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","02315","VXUS","BK0216","BK4585","BK1161","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635214982","title":"Asian Stocks Estimated To Be Trading Below Fair Value In May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635214982","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635214982?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:04","pubTimestamp":1778623461,"startTime":"0","endTime":"0","summary":"As of May 2026, Asian markets have shown resilience with Chinese equities advancing and Japan's indices reaching record highs, driven by strong domestic demand and optimism in technology sectors. In this environment, identifying undervalued stocks can be an attractive strategy for investors seeking opportunities where market prices may not fully reflect a company's intrinsic value.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8212000-choice1-main-header/1585186704996","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8212000-choice1-main-header/1585186704996"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/semiconductors/hkg-6865/flat-glass-group-shares/news/asian-stocks-estimated-to-be-trading-below-fair-value-in-may","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/semiconductors/hkg-6865/flat-glass-group-shares/news/asian-stocks-estimated-to-be-trading-below-fair-value-in-may","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK6018","02315","ITS.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143907967","title":"BIOCYTOGEN-B Shares Surge Over 6% in Afternoon Trading on Announcement of Major Project Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1143907967","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143907967?lang=en_us&edition=fundamental","pubTime":"2026-05-12 14:00","pubTimestamp":1778565628,"startTime":"0","endTime":"0","summary":"BIOCYTOGEN-B (02315) saw its shares rise more than 6% in afternoon trading. At the time of writing, the stock was up 6.2%, trading at HK$54.8 with a turnover of HK$48.46 million. The increase follows...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK1161","688796","BK0216","BK4585","BK4588","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159470505","title":"Biocytogen-B Shares Surge Over 9% as First-Quarter Net Profit Soars Nearly Ninefold to RMB104 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1159470505","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159470505?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:02","pubTimestamp":1777341731,"startTime":"0","endTime":"0","summary":"Biocytogen-B (02315) saw its shares rise more than 9% during the trading session. By the time of writing, the gain had narrowed slightly to a modest increase of 1.61%, with the share price currently...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02315","BK0216","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150363873","title":"Stock Track | BIOCYTOGEN-B Soars 9.18% in Early Trading on Strong Q1 Earnings and Major R&D Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1150363873","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150363873?lang=en_us&edition=fundamental","pubTime":"2026-04-28 09:59","pubTimestamp":1777341555,"startTime":"0","endTime":"0","summary":"BIOCYTOGEN-B's stock price soared 9.18% during early trading on Tuesday, reflecting strong investor sentiment towards the company.The surge follows the release of the company's first-quarter 2026...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133299273","title":"BIOCYTOGEN-B Shares Surge Over 9% in Morning Session on Strong Q1 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1133299273","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133299273?lang=en_us&edition=fundamental","pubTime":"2026-04-28 09:57","pubTimestamp":1777341425,"startTime":"0","endTime":"0","summary":"BIOCYTOGEN-B (02315) rose more than 9% during early trading. At the time of writing, the stock was up 7.65% to HK$63.35, with a turnover of HK$54.1856 million. The company reported its first-quarter...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","02315","VXUS","BK4588","BK1161","BK4585","688796"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630952803","title":"Biocytogen Pharmaceuticals Turns to Profit in Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2630952803","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630952803?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:45","pubTimestamp":1777290344,"startTime":"0","endTime":"0","summary":"Biocytogen Pharmaceuticals   recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02315"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106583514","title":"BIOCYTOGEN-B Reports Q1 Profit Turnaround with 104 Million Yuan Net Income","url":"https://stock-news.laohu8.com/highlight/detail?id=1106583514","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106583514?lang=en_us&edition=fundamental","pubTime":"2026-04-27 16:38","pubTimestamp":1777279108,"startTime":"0","endTime":"0","summary":"BIOCYTOGEN-B (02315) announced its first-quarter results for the three months ended March 31, 2026. The group recorded revenue of 433 million yuan, representing a 73.68% increase year-over-year. Net...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02315","BK0216","688796"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bbctg.com.cn","stockEarnings":[{"period":"1week","weight":0.2629},{"period":"1month","weight":0.4319},{"period":"3month","weight":-0.0025},{"period":"6month","weight":0.3598},{"period":"1year","weight":1.8499},{"period":"ytd","weight":0.6671}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":-0.0065},{"period":"3month","weight":-0.0649},{"period":"6month","weight":-0.0806},{"period":"1year","weight":0.0037},{"period":"ytd","weight":-0.037}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Biocytogen Pharmaceuticals (Beijing) Co Ltd is a China-based company primarily engaged in the provision of innovative animal models and pre-clinical pharmaceutical research and development services based on its independently developed gene-editing technology. The Company utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Company’s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The Company is also engaged in the provision of gene-editing services. The Company operates its businesses in the domestic market and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.018702},{"month":2,"riseRate":0.75,"avgChangeRate":0.087225},{"month":3,"riseRate":0.5,"avgChangeRate":0.15364},{"month":4,"riseRate":0.25,"avgChangeRate":-0.063264},{"month":5,"riseRate":0.5,"avgChangeRate":0.097922},{"month":6,"riseRate":0.25,"avgChangeRate":-0.005144},{"month":7,"riseRate":0.5,"avgChangeRate":0.039703},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.055975},{"month":9,"riseRate":0.666667,"avgChangeRate":0.092895},{"month":10,"riseRate":0.25,"avgChangeRate":-0.096483},{"month":11,"riseRate":0.5,"avgChangeRate":0.009059},{"month":12,"riseRate":0.5,"avgChangeRate":0.137663}],"exchange":"SEHK","name":"BIOCYTOGEN-B","nameEN":"BIOCYTOGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BIOCYTOGEN-B(02315),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BIOCYTOGEN-B(02315) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BIOCYTOGEN-B,02315,BIOCYTOGEN-B股票,BIOCYTOGEN-B股票老虎,BIOCYTOGEN-B股票老虎国际,BIOCYTOGEN-B行情,BIOCYTOGEN-B股票行情,BIOCYTOGEN-B股价,BIOCYTOGEN-B股市,BIOCYTOGEN-B股票价格,BIOCYTOGEN-B股票交易,BIOCYTOGEN-B股票购买,BIOCYTOGEN-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BIOCYTOGEN-B(02315),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BIOCYTOGEN-B(02315) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}